KemPharm Issues Letter to Shareholders
January 24, 2023 07:30 ET
|
KemPharm
CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for...
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
January 18, 2023 07:30 ET
|
KemPharm
CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare...
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
January 11, 2023 07:30 ET
|
KemPharm
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm,...
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
January 09, 2023 06:30 ET
|
KemPharm
Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial...
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
December 21, 2022 07:30 ET
|
KemPharm
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and...
KemPharm Announces Appointment of Christopher Posner as New Independent Director
November 29, 2022 07:30 ET
|
KemPharm
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc....
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
November 18, 2022 07:30 ET
|
KemPharm
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH)...
KemPharm Reports Third Quarter 2022 Results
November 09, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA...
KemPharm to Report Third Quarter 2022 Financial Results
November 01, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
October 04, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...